Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that it has received a new patent for its buccal drug delivery platform technologies. The Canadian Intellectual Property Office has granted to Generex Canadian Patent No. 2,354,148, a patent titled Aerosol Formulations for Buccal and Pulmonary Application.
This new patent increases the number of issued patents related to the Company's buccal drug delivery platform technologies to 162. A total of 101 patent applications in the field remain pending.
"We continue to augment the breadth and depth of the intellectual property protection for our drug delivery platform," observed Rose C. Perri, the Company's Chief Operating Officer, "as we continue to pursue the platform's commercialization opportunities for insulin and other active pharmaceutical ingredients."
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy